The latest biotech news

News and Trends 14 Sep 2016

Novartis invests in Irish Upstart tackling Chronic Inflammation

Dublin-based Inflazome has made a splashy debut by closing Series A with €15M. The company will use these funds to develop therapies targeting inflammasome-based chronic diseases. Chronic inflammation might sound like a minor livable irritation, but it can be deadly. Think Multiple Sclerosis, Rheumatoid Arthritis, and Lupus. It’s also one of the most lucrative fields […]

September 14, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 14 Sep 2016

How to be a Serial Biotech Entrepreneur in Europe with Philippe Dro

Not many people are as successful as entrepreneur Philippe Dro: he is one of the very few serial Biotech entrepreneurs in Europe. He is a founder or early backer of three Biotech or Medtech companies that have since been acquired by big Pharma, all in less just 15 years! I had a nice chat with Dro […]

September 14, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 13 Sep 2016

The next generation of Antibiotics could be Bacteriophages

One of the last remaining bastions for organic chemists in pharmaceuticals is in antibiotic development. It is now under fire from a partnership of academic and industrial microbiologists, who are developing bacteriophages into antibacterial therapies. A team of researchers headed by Dr. Janet Neal and Prof. Martha Clokie at the University of Leicester demonstrated the […]

September 13, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

Horizon Pharma successfully negotiates Acquisition of US Competitor for €712M

Perhaps having learned from its Depomed debacle last year, Horizon Pharma has lined up a successful acquisition of another competitor, Raptor Pharmaceuticals, for €712M ($800M). Last summer, the Irish company, Horizon Pharma, wouldn’t take no for an answer in its overtures to acquire Depomed, an American speciality pharmaceutical company. It was rejected not once but twice, […]

September 13, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

Reviewing CRISPR, the Scientific Discovery of the Century

What’s happening with CRISPR these days? Another company just filed for an IPO, documents relevant to CRISPR patent war have come to light, research is moving forward, and the therapy is one step closer to the clinic. In this review, we discuss why the exciting new technology and the drama surrounding it: big money, no clinical […]

September 13, 2016 - 8 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

Celyad’s unique CAR-T approach is ready for Efficacy Studies

The Belgian company has completed a successful Phase I trial for its NKR-2 T-cell therapy in patients with Leukemia and Myeloma, with no safety issues or dose-limiting toxicity reported. Celyad can now embark on efficacy studies. Celyad definitely has an original story. The company started back in 2007 as Cardio3Bioscience, targeting cardiovascular diseases with cell therapy, but […]

September 12, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

Sanofi & Google Joint Venture could Revolutionize Diabetes

Sanofi and Verily, formerly Google Life Sciences, have signed a deal to form a €444M joint venture, Onduo. Its aim is to integrate medicine and microelectronics to tackle diabetes. Steve Jobs prophesied that “the biggest innovations of the twenty-first century will be the intersection of biology and technology,” and it appears that Verily, a division of […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Classical music, the Danube, Schnitzel, and apple strüdel – a typical combination of Vienna. The city has also been at the top of rankings for quality of life, innovation, and popular host for conferences. But what about Biotech? Once one of the most influential cities in Europe, Vienna might now be somewhat under the radar […]

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 10 Sep 2016

This Dutch BioArtist could be the Mistress of Natural Forces

Roos Meerman is a force to be reckoned with in the BioArt world – she has been racking up awards and just took home the 2016 BioArt & Design Award. Her work focuses on the manipulation of materials with natural forces like sound and temperature. Roos Meerman is a Dutch bioartist whose work on natural […]

September 10, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 9 Sep 2016

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

After Vienna, it’s time to jump in the middle of the Paris-Amsterdam-Frankfurt triangle in the BioPark of Brussels South in Belgium. We will meet a company who can answer the problem of antibiotic use in the bacterial strains selection whilst, at the same time, increasing bioproduction yield. Our Biotech of the week, Delphi Genetics. City: Gosselies […]

September 9, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 9 Sep 2016

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

A German biotech has surfaced with a promising new drug for traumatic brain injury: vasopharm’s Nitrous Oxide Synthase inhibitor is starting Phase III. In news from the novel and obscure, someone has taken an interest in Nitrous Oxide Synthase (NOS). That someone is vasopharm GmbH, a small German biopharmaceutical company interested in cerebrovascular diseases. The company has […]

September 9, 2016 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Novartis invests in Irish Upstart tackling Chronic Inflammation

How to be a Serial Biotech Entrepreneur in Europe with Philippe Dro

The next generation of Antibiotics could be Bacteriophages

Horizon Pharma successfully negotiates Acquisition of US Competitor for €712M

Reviewing CRISPR, the Scientific Discovery of the Century

Celyad’s unique CAR-T approach is ready for Efficacy Studies

CRISPR Therapeutics applies to go Public in another Massive IPO

Sanofi & Google Joint Venture could Revolutionize Diabetes

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

This Dutch BioArtist could be the Mistress of Natural Forces

How to get Antibiotic free Bioproduction in Biotech with Delphi Genetics

Novel biopharma’s therapy for Traumatic Brain Injury heads to Phase III

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!